XenTech is a Patient-Derived Tumor Xenograft platform

Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

Database access

Search your model into our PDX library

Login :

Password :

> Create an account

Latest news

July 2017 | ITCC-P4 official launch

XenTech is proud to be part of the ITCC-P4, a new platform to accelerate drug development for children and adolescents dying of cancer. It has been several years since XenTech developed pediatric PDX especially liver cancer PDX. Children and adolescents cancers need to be studied since the preclinical research aside from adult cancers. At XenTech, […]


Contract Research Organization

XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....


Research collaborations

XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...